US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% META $728.08 ▲+0.00% NVDA $233.95 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% JNJ $256.03 ▲+0.00% SPCX $158.96 ▲+0.00%
FinancialContent

Alto Neuroscience, Inc. Common Stock (NY:ANRO)

24.80 UNCHANGED
Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alto Neuroscience, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Possible Securities Fraud
Via ACCESSWIRE
News headline image
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm
Via ACCESSWIRE
News headline image
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Nasdaq Down 2%; US Crude Stocks Increase ↗
 
Via Benzinga
News headline image
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform ↗
Alto Neuroscience's ALTO-100 Phase 2b study for major depressive disorder failed to meet its primary endpoint, but the company plans further data analysis and studies. 
Via Benzinga
News headline image
Gold Moves Lower; AT&T Earnings Top Views ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss ↗
 
Via Benzinga
Topics Stocks
News headline image
Enphase Energy Posts Downbeat Results, Joins McDonald's, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
ANRO Stock Earnings: Alto Neuroscience Beats EPS for Q2 2024 ↗
ANRO stock results show that Alto Neuroscience beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On ↗
Under-the-radar stocks offer incredible chances at massive returns with these shares representing compelling choices for investors. 
Via InvestorPlace
News headline image
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024 ↗
ANRO stock results show that Alto Neuroscience missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >